Unidad de Fases I - START Madrid

Unidad de Fases I - START Madrid

o   Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181, a monoclonal antibody, in Subjects with Advanced Solid Tumors (M15-891).

Investigador Principal: Dra. María José de Miguel Luken

Más información aquí

 


o   An open label, Phase 1, first-in-human study of the safety and tolerability of TRAIL receptor agonist ABBV-621 in subjects with previously-treated solid tumors and hematologic malignancies (M15-913).

Investigador Principal: Dr. Emiliano Calvo Aller

Más información aquí

 

o   A Phase I, Multicenter, Open-label Safety, Pharmacokinetic and Preliminary Efficacy Study of Wild-type Sparing EGFR Inhibitor, AC0010MA, in Adult Patients with Previously Treated EGFRmut and Acquired T790M Mutation Non-Small Cell Lung Cancer (NSCLC) (AC00102014-101).

Investigador Principal: Dra. María José de Miguel Luken

Más información aquí

 


o   A safety, tolerability and pharmacokinetic dose escalation and expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin (AMC303-01).

         Investigador Principal: Dr. Emiliano Calvo Aller

         Más información aquí

 

o   A Phase 1, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination With Systemic Pembrolizumab (MASTERKEY-318) (20140318).

Investigador Principal: Dr. Antonio Cubillo Gracián

Más información aquí

 


o   An Open-label Non-randomised, Multicentre, Comparative, Phase I study to compare the Pharmacokinetics, Safety and Tolerability of AZD9291 Following a single oral 80 mg Dose to Patients with Advanced Solid Tumours and Normal Renal Function or Severe Renal Impairment (D5160C00035).

Investigador Principal: Dra. María José de Miguel Luken

Más información aquí

 

 

o   Phase 1b multi-indication study of anetumab ravtansine (BAY 94-9343) in patients with mesothelin expressing advanced or recurrent malignancies (BAY15384).

Investigador Principal: Dra. María José de Miguel Luken

Más información aquí

 


o   A Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors (BGB-290-103).

Investigador Principal: Dr. Emiliano Calvo Aller

Más información aquí

 


o   A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors (CA017-003).

Investigador Principal: Dr. Emiliano Calvo Aller

         Más información aquí

 

o   A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027-002).

Investigador Principal: Dr. Emiliano Calvo Aller

Más información aquí

 


o   Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects with Virus-Positive and Virus-Negative Solid Tumors (CA209-358).

Investigador Principal: Dra. Valentina Boni

Más información aquí

 


o   An open-label, dose-finding and proof of concept study of the PD-L1 probodytm therapeutic, CX-072, as mnotherapy and in combination with ipilumab or with zelboraf in anti-PD-L1 inhibito naïve subjetcs with advanced or recurrent solid tumors or lymphomas (CTMX-M-072-001).

Investigador Principal: Dra. Valentina Boni

Más información aquí

 

o   A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First in Human Study in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors (CTMX-M-2009-01).

Investigador Principal: Dra. Valentina Boni

 


o   A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC‑9545 Alone or In Combination with Palbociclib and/or LHRH Agonist in Patients with Locally Advanced OR Metastatic Estrogen Receptor-Positive Breast Cancer (GO39932).

Investigador Principal: Dra. Valentina Boni

Más información aquí

 


o   An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma (H3B6527-G000-101).

Investigador Principal: Dra. María José de Miguel Luken

Más información aquí

 


o   An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia (H3B-8800-G000-101).

Investigador Principal: Dr. Jaime Pérez de Oteyza

Más información aquí

 


o   A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (INCB 01158-101).

Investigador Principal: Dra. María José de Miguel Luken

         Más información aquí

 

o   A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors (INCMGA00012).

Investigador Principal: Dr. Emiliano Calvo Aller

Más información aquí

 

 

o   A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with Selected FGFR Gene Alterations (BCL2002)

Investigador Principal: Dr. Jesús García-Donas Jiménez

 


o   A Phase 1, Open-Label Study of the Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107, an Agonistic Human Monoclonal Antibody Targeting CD40 in Patients with Advanced Stage Cancer (JNJ-64457107).

Investigador Principal: Dr. Emiliano Calvo Aller

Más información aquí

 


o   A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancers (JNJ-63723283).

Investigador Principal: Dr. Emiliano Calvo Aller

Más información aquí

 


o   A fase 1b-2, de niraparib en combinación con Anti PD-1 en pacientes con cáncer de próstata metastásico resistente a castración.

Investigador Principal: Dra. Valentina Boni

Más información aquí

 


o   An Open-label, Multicenter, Phase 1b Study of JNJ-63723283, a PD-1 inhibitor, Administered in Combination with Apalutamide in Subjects with Metastatic Castration-Resistant Prostate Cancer (JNJ-5602192 PCR2032).

Investigador Principal: Dra. Valentina Boni

Más información aquí

 


o   A Phase 1 First-in-Human Study of KO-947 in Locally Advanced Unresectable or Metastatic, Relapsed and/or Refractory Non-Hematological Malignancies (KO-ERK-001).

Investigador Principal: Dra. Valentina Boni

Más información aquí

 


o   An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies with HRAS Mutations (KO-TIP-001)

Investigador Principal: Dra. Valentina Boni

Más información aquí

 


o   A Phase 1a/1b Study of LY3321367, a Novel Anti-TIM-3 Antibody, Administered Alone or in Combination with LY3300054, an Anti-PD-L1 Antibody, in Advanced Refractory Solid Tumors (I9A-MC-JLDA).

Investigador Principal: Dr. Emiliano Calvo Aller

Más información aquí


o   Solid tumors Anti-PD-L1 (I8J-MC-JYCA).

Investigador Principal: Dra. María José de Miguel Luken

Más información aquí

 


o   A Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors Harboring RET Alterations (LOXO-RET 17001).

Investigador Principal: Dra. Valentina Boni

Más información aquí

 


o   A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors (LOXO TRK 15002)

Investigador Principal: Dra. Valentina Boni

Más información aquí

 


o   A phase 1/2 , open-label, multicenter, dose escalation and dose expansión study of NKTR-214 and anti-PD-L1 (atezolizumab) or anti-PD-1 (nivolumab, pembrolizumab) in patients with selected locally advanced or metastatic solid tumor malignancies (16-214-02).

Investigador Principal: Dra. María José de Miguel Luken

Más información aquí

 


o   Phase I Study of MEN1309, a CD205 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With CD205-Positive Metastatic solid tumours and non-Hodgkin Lymphoma (MEN1309-01).

Investigador Principal: Dra. María José de Miguel Luken

Más información aquí


 

o   Men1611-01, open-label, multicenter, phase IB dose escalation study of MEN1611, a PI3K inhibitor combined with trastuzumab ± fulvestrant, in subjetcs with PIK3CA mutated HER2 positive locally recurrent unresectable (advanced) or metastatic (A/M) breast cáncer progressed to anti-HER2 based therapy (MEN1611-01).

Investigador Principal: Dra. María José de Miguel Luken

Más información aquí

 

 

​ 

To Top